Details for New Drug Application (NDA): 021627
✉ Email this page to a colleague
The generic ingredient in NAMENDA is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.
Summary for 021627
Tradename: | NAMENDA |
Applicant: | Allergan |
Ingredient: | memantine hydrochloride |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021627
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Apr 18, 2005 | TE: | RLD: | Yes |
Expired US Patents for NDA 021627
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | NAMENDA | memantine hydrochloride | SOLUTION;ORAL | 021627-001 | Apr 18, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Allergan | NAMENDA | memantine hydrochloride | SOLUTION;ORAL | 021627-001 | Apr 18, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription